HOME >> MEDICINE >> NEWS
New data shows prescribers how to cut the cost of schizophrenia care while relieving patient distress

A major new study evaluating the cost-effectiveness (1,901 patients, 61 centres, 9 countries) of atypical antipsychotics in schizophrenia have shown that treatment with Risperdal (risperidone) is 50% less expensive than olanzapine, with no difference in clinical outcomes1.

Professor Martin Knapp, professor of Social Policy at the London School of Economics explained, "The major costs of treating schizophrenia result from hospitalisation, with drug costs only accounting for less than 5 percent of the direct medical costs. We already know that atypical antipsychotics are clinically superior to conventional antipsychotics and this in itself has cost saving implications. Indeed, treatment with the atypical antipsychotic Risperdal has been shown to reduce the risk of relapse by as much as 30% when compared to an older therapy such as haloperidol2".

The objective of the RODOS pharmacoeconomic study (Risperidone Olanzapine Drug Outcomes study in Schizophrenia conducted by the Janssen Research Foundation) was to compare the cost-effectiveness of two atypical antipsychotic medications, Risperdal and olanzapine, in the treatment of schizophrenia in a naturalistic clinical setting.

Study results showed that the daily cost of the studied medication was 50% higher for olanzapine than for Risperdal (mean $6.50 USD +/- $2.30 for olanzapine versus $3.70 USD +/- $1.90 for Risperdal) and this evidence was consistent and conclusive across all countries and centres (p<0.0001). Total costs for all inpatient drug use were also significantly different (p<0.0001) and were substantially higher in the olanzapine group than in the Risperdal group (mean $297.5 +/- $301.10 USD for olanzapine versus mean $159.9 +/- $183.3 USD in Risperdal group). Patients treated with Risperdal were also discharged sooner than patients being treated with olanzapine. This result was reflected in the shorter length of stay in hospital among Risperdal patients (mean 43.6 days versus 47.4 d
'"/>

Contact: Roseann Ward
tamsin.page@ketchumcomms.co.uk
44-7780-990848
Ketchum
26-Apr-2000


Page: 1 2

Related medicine news :

1. Study shows promise in identifying kidney failure
2. Study shows patch therapy may be as effective as oral medications
3. Study shows soy is well accepted in school lunches
4. Chronic pain treatments more effective when taken together, new study shows
5. UW study shows blacks and Latinos are more satisfied with physicians of the same race
6. Vaccine against childhood pneumonia shows promise
7. UW research shows risk factors for relapse among health care professionals who abuse drugs
8. Study shows use of budesonide reduced the risk of asthma related events by 40% in children
9. New technique shows promise for improved straightening of crooked nose
10. Chemical decoy shows promise for slowing Alzheimers by acting as decoy
11. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/21/2020)... (PRWEB) , ... February 21, 2020 , ... Dr. Stong, ... strong advocate for giving back. He has been a long-time volunteer with Healing ... goal of this particular HTC trip is to provide cleft lip and palate procedures ...
(Date:2/21/2020)... ... 21, 2020 , ... The American Society for Clinical Pathology ... Boston, MA, in October 2021. The prestigious, invitation-only event—organized by the Union for ... of health, city and industry leaders, senior executives and other influential players ...
(Date:2/20/2020)... (PRWEB) , ... February 20, 2020 , ... ... agents, has a new release with next generation API integration functionality which ... by VisitorsCoverage Inc. in 2017, TMQuotes was the first white label ...
(Date:2/19/2020)... ... 2020 , ... MedTech IGNITE Expands Steering Committee, Faculty and ... 2020 Cohort , The Massachusetts Medical Device Industry Council ( MassMEDIC ) announced ... startup founders and CEOs to participate in the 2020 IGNITE Cohort. , ...
(Date:2/19/2020)... ALPHARETTA, Ga. (PRWEB) , ... February 19, 2020 ... ... to announce they are holding a CoolEvent for FDA-cleared CoolSculpting®, the world’s most ... at 6345 Halcyon Way, Suite 850 in the Halcyon Village Center in Alpharetta, ...
Breaking Medicine News(10 mins):
(Date:2/19/2020)... ... February 19, 2020 , ... Aspire Regenerative, a leader in offering therapies ... Pharmacy for a free weight-loss event on March 1, 2020. It will take place ... Jolla, CA, 92037. , During the event, physicians and pharmacists will lead an informative ...
(Date:2/19/2020)... ... February 19, 2020 , ... Drs. Mario Canal and Ben Calem ... 2020 at The Mansion in Voorhees. The course features guest speaker, Dr. Amanda Seay, ... Dental implants, including All-on-4® full mouth dental implants, are a major ...
(Date:2/19/2020)... ... February 19, 2020 , ... The Team Type 1 ... to medicine for everyone affected by diabetes, announced a partnership with VeloCity, a fundraising ... The third annual VeloCity event takes place on May 2nd and begins on the ...
Breaking Medicine Technology:
Cached News: